Electroconvulsive Therapy

• Seizure-induced neurotransmitter modulation: The electrically induced generalized seizure triggers massive release and subsequent reuptake of monoamine neurotransmitters—specifically serotonin, norepinephrine, and dopamine—at concentrations vastly exceeding those achieved by pharmacotherapy alone. This acute neurochemical surge is followed by adaptive downregulation of postsynaptic receptors (particularly β-adrenergic and serotonin-2A receptors), which correlates with antidepressant response. The repeated nature of ECT treatments (typically 6-12 sessions) leads to sustained neurotransmitter system remodeling, with increased expression of brain-derived neurotrophic factor (BDNF) and activation of cascades supporting neuronal survival and plasticity.

• Hypothalamic-pituitary-adrenal (HPA) axis normalization: Severe depression is associated with persistent HPA axis hyperactivity, characterized by elevated baseline cortisol, blunted feedback suppression on dexamethasone suppression testing, and increased CRH (corticotropin-releasing hormone) levels. ECT acutely increases ACTH and cortisol release during and immediately after the procedure; however, with repeated treatments, there is progressive normalization of HPA axis function, including restored cortisol diurnal rhythm and improved negative feedback regulation. This normalization of the stress-response system is believed to contribute substantially to mood stabilization, particularly in patients with melancholic features and elevated pretreatment cortisol levels.

• GABAergic system enhancement and seizure threshold elevation: ECT paradoxically works by inducing seizures yet increasing seizure threshold across successive treatments—a phenomenon termed "seizure threshold titration." This occurs through upregulation of GABA-A receptor function and expression, leading to enhanced GABAergic inhibitory tone in mood-regulating circuits. The increase in seizure threshold (typically 25-50% after a course of ECT) is associated with therapeutic benefit, suggesting that the anticonvulsant effects achieved through repeated treatments contribute to mood stabilization by reducing neural hyperexcitability in limbic and prefrontal circuits implicated in mood regulation.

• Neuroendocrine changes and thyroid hormone dynamics: ECT increases circulating thyroid hormone levels acutely and leads to chronic alterations in thyroid function. Elevated thyroid hormone, particularly in the context of the antidepressant response, may potentiate monoaminergic signaling through increased adrenergic receptor density and enhanced norepinephrine reuptake inhibition. Additionally, ECT increases prolactin levels, which may reflect dopamine antagonism in the tuberoinfundibular pathway, potentially contributing to anxiolytic and antipsychotic effects observed clinically.

• Neuroinflammation reduction and microglial modulation: Recent evidence demonstrates that severe depression involves neuroinflammatory processes characterized by activation of microglia, elevated pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), and increased blood-brain barrier permeability. ECT reduces microglial activation markers and diminishes pro-inflammatory cytokine production, shifting the microglial phenotype from pro-inflammatory (M1) to anti-inflammatory (M2) states. This immunomodulatory effect addresses a fundamental pathobiological feature of treatment-resistant depression and may explain ECT's efficacy in depressed patients with elevated inflammatory biomarkers.

• Neuroplasticity enhancement and synaptogenesis: ECT robustly increases expression of neurotrophic factors—particularly BDNF, NGF (nerve growth factor), and GDNF (glial-derived neurotrophic factor)—in hippocampus, prefrontal cortex, and other mood-regulating regions. This triggers downstream signaling cascades involving TrkB and p75 receptors that promote dendritic sprouting, increased synaptic density, and enhanced long-term potentiation (LTP) in circuits involving the hippocampus and dorsolateral prefrontal cortex. The neuroimaging correlate is increased hippocampal volume, which has been observed after ECT courses and correlates with antidepressant response and improved cognitive performance.

• Prefrontal-limbic circuit rebalancing: Neuroimaging studies demonstrate that severe depression involves hyperactivity of limbic structures (amygdala, insula) and hypoactivity of prefrontal regulatory regions (dorsolateral prefrontal cortex, anterior cingulate cortex). ECT normalizes this functional imbalance through multiple mechanisms: it directly increases prefrontal cortex activity while reducing limbic hyperreactivity, restores effective prefrontal-limbic connectivity, and enhances cognitive control circuits. This rebalancing is associated with improved emotion regulation, reduced rumination, and decreased threat sensitivity—core features of depressive recovery.

• Severe major depressive disorder (MDD) with psychotic features: Patients with severe depression accompanied by mood-congruent psychosis (e.g., delusions of worthlessness, guilt, poverty, or nihilistic themes) show particularly robust response to ECT, with remission rates exceeding 80-90%. The presence of psychotic features indicates greater severity and reduced responsiveness to antidepressants alone, making ECT an especially appropriate first-line consideration. Melancholic features (early morning awakening, psychomotor changes, vegetative symptoms) also predict superior ECT response compared to atypical depression.

• Treatment-resistant depression (TRD): Defined as failure of adequate trials (≥8 weeks at therapeutic doses) of ≥2 antidepressants from different pharmacological classes, TRD occurs in approximately 30-40% of depressed patients and is the most common indication for ECT in contemporary practice. The pathophysiology underlying TRD likely involves greater neurobiological severity—including more pronounced HPA axis dysregulation, neuroinflammation, and neurotrophic factor deficiency—which ECT uniquely addresses through multiple simultaneous mechanisms unavailable to pharmacotherapy.

• Acute suicidality with intent and plan: Patients with imminent suicide risk (active planning, specific method, expressing intent to die imminently) represent a psychiatric emergency requiring the most rapidly effective intervention available. ECT typically produces clinical improvement within 2-4 sessions—far more rapidly than the 2-4 week lag typical of pharmacotherapy—making it a critical life-saving intervention. The speed of ECT response in reducing suicidal ideation and hopelessness makes it uniquely valuable in this high-risk population.

• Catatonia: Both excited catatonia (agitation, waxy flexibility, echolalia) and retarded catatonia (mutism, immobility, negativism) respond to ECT with particular efficacy. Catatonia may occur primary (psychiatric) or secondary to medical conditions (neuroleptic malignant syndrome, malaria, encephalitis); ECT addresses the catatonic syndrome itself regardless of etiology, making it invaluable in otherwise therapeutically intractable presentations. The presumed mechanism involves restoration of thalamocortical connectivity disrupted in catatonic states.

• Bipolar disorder—acute mania with psychosis: Patients with acute bipolar I mania accompanied by psychotic features (grandiose delusions, command hallucinations) or with severe behavioral dyscontrol, aggression, or dangerous behavior represent indications for ECT, particularly when rapid tranquilization is necessary. ECT's combination of mood-stabilizing and antipsychotic effects makes it especially valuable in this context, particularly in patients who cannot tolerate or have failed trials of mood stabilizers and antipsychotics.

• Neuroleptic malignant syndrome (NMS): While benzodiazepines and dopamine agonists constitute first-line management, ECT is a critical alternative in patients with NMS refractory to conservative measures, as it addresses the underlying severe dysregulation of dopaminergic and temperature-regulating systems through its multiple neurobiological mechanisms.

• Medication intolerance or contraindication: Patients with medical comorbidities precluding use of antidepressants (active cardiac arrhythmias, severe hyponatremia from SIADH, uncontrolled seizure disorder, etc.) may benefit from ECT as an alternative intervention without the pharmacokinetic burden of systemic medications.

• Pregnancy with severe depression: Pregnant patients with severe untreated depression face both the teratogenic risks of antidepressant exposure and the substantial risk of postpartum depression and infanticide. ECT is considered safe in pregnancy (particularly in the second and third trimesters) and is often preferred over initiating psychotropic medications during gestation, as it has no known teratogenic effects and can be rapidly effective.

• Severe depression precipitating ECT: Patients present with profound depressed mood unresponsive to psychopharmacology, typically accompanied by anhedonia, hopelessness, helplessness, and suicidal ideation with concrete planning. Vegetative symptoms predominate: marked insomnia (particularly early morning awakening at 3-4 AM), appetite suppression with significant weight loss (often 10-20 lbs), and profound fatigue with decreased energy despite sleep. Psychomotor retardation is marked, with slowed speech, reduced facial expressiveness, and difficulty initiating activities. In patients with psychotic features, mood-congruent delusions may include conviction of being worthless, evil, or the cause of others' suffering; nihilistic delusions; or Cotard-like beliefs about being dead or rotting.

• Acute suicidality requiring ECT: These patients express clear, detailed suicide plans; demonstrate access to lethal means; and communicate imminent intent to die, often with a sense of urgency and desperation. Hopelessness—the conviction that the situation is unchangeable and the future is bleak—is a cardinal feature distinguishing high-risk suicidal patients from those with passive death wishes. They often communicate finality ("I've made my decision," "everyone will be better off"), show decreased emotional expression, and may exhibit unexpected calmness after deciding to die.

• Catatonia: Patients display marked waxy flexibility (limbs maintain imposed positions without active resistance), mutism (selective or complete absence of speech), negativism (resistance to passive movement), echolalia or echokinesia (repetition of words or mimicry of gestures), posturing (adoption of unusual sustained body positions), and psychomotor retardation progressing to complete immobility. In excited catatonia, agitation, impulsivity, and pressured speech predominate with retained muscle tone. Patients may display automatic obedience (performing movements requested by others despite instruction not to) or ambitendency (apparent difficulty completing volitional movements, starting and stopping repeatedly).

• Acute mania with psychosis: Patients present with expansive or irritable mood disproportionate to circumstances, decreased need for sleep (feeling rested after 2-3 hours), flight of ideas with pressured speech, and grandiose ideation. In psychotic mania, this is accompanied by grandiose delusions ("I am God," "I have special powers," "I am chosen for a great mission") and sometimes command hallucinations instructing dangerous behavior. Increased goal-directed activity manifests as excessive engagement in pleasurable activities with high potential for harm (spending sprees, sexual promiscuity, reckless driving, aggressive confrontations).

• Physical examination findings in treated patients: During and immediately post-ECT, patients display post-ictal confusion (typically resolving within 30-60 minutes), disorientation to time and place (though orientation to person typically preserved), and retrograde amnesia for the procedure and preceding hours. Memory for remote events is generally intact. Patients may exhibit transient tachycardia and hypertension (peaking 1-2 minutes post-ictal) and mild muscle soreness from the anesthesia-induced paralysis. After a course of ECT, mood is markedly improved, energy restored, suicidal ideation resolved or substantially diminished, and appetite normalized.

• Clinical variants: Ultra-rapid cycling bipolar disorder (distinct from seasonal pattern, showing mood shifts within days to hours) may show preferential response to ECT over traditional mood stabilizers. Depressive stupor—severe depression with near-complete unresponsiveness to external stimuli and minimal verbal output—represents a psychiatric emergency particularly responsive to ECT. Atypical depression (hypersomnia, appetite increase, mood reactivity, leaden paralysis) shows slower response to ECT than melancholic depression but still responds better to ECT than to pharmacotherapy.

• Diagnostic criterion: Treatment-resistant depression (TRD) as primary ECT indication: TRD is diagnosed by documented failure of ≥2 adequate antidepressant trials (each ≥8 weeks duration at therapeutic doses—e.g., sertraline ≥150 mg/day, venlafaxine ≥225 mg/day XR, tricyclic antidepressants at plasma levels 100-300 ng/mL) from different pharmacological classes without achieving remission (≥50% symptom reduction or PHQ-9 score <5). Augmentation strategies (lithium, T3 thyroid hormone, atypical antipsychotics) applied for ≥4 weeks without response further establishes TRD diagnosis. Operationally, the Thase-Sullivan staging system stratifies TRD severity: Stage I (failure of 1 adequate trial), Stage II (2 trials), Stage III (3 trials or 1 trial plus adequate augmentation), Stage IV (4+ trials or 2+ trials with augmentation). ECT is typically offered at Stage III-IV but may be considered earlier in severe presentations.

• Severity assessment for psychotic depression: The CORE (Consensus on Rating ECT Competency) assessment evaluates depression severity using HAM-D-17 (Hamilton Depression Rating Scale, scores ≥25 indicating severe depression), presence of psychotic features (confirmed via SCID-IV or clinical interview demonstrating mood-congruent delusions), and functional impairment (inability to work, self-care, or maintain safety). Psychotic depression shows superior ECT response (remission >80%) compared to non-psychotic severe depression (remission ~70%), with remission defined as HAM-D-17 ≤7 or IDS-C-30 ≤10.

• Suicide risk stratification: The Columbia Suicide Severity Rating Scale (C-SSRS) quantifies suicidality on dimensions of ideation (frequency, intensity, control), behavior (actual attempts, preparatory behavior, aborted/interrupted attempts), and lethality. Patients with acute suicidal ideation with specific plan and intent (C-SSRS ideation subscale ≥4) and recent preparatory behavior represent acute ECT candidates. The Scale for Suicide Ideation (SSI) provides additional quantification, with scores >9 indicating moderate-to-high acute suicide risk requiring rapid intervention.

• Catatonia diagnostic criteria: The Bush-Francis Catatonia Rating Scale (BFCRS) assesses 14 motor signs: mutism, posturing, waxy flexibility, negativism, gegenhalten (resistance to passive movement), ambitendency, stereotypy, mannerisms, grimacing, echolalia, echokinesia, verbigeration, rigidity, and tremor. Diagnosis requires ≥2 of these 14 signs; ≥4 signs indicates definite catatonia. The presence of catatonia identifies patients requiring ECT consideration, with ~90% remission of catatonic features in appropriately treated patients.

• Mania severity and psychotic features assessment: The Young Mania Rating Scale (YMRS) quantifies mania severity (scores >20 indicating moderate-to-severe mania). Presence of mood-congruent psychosis (grandiose delusions,

Before the first treatment

• Capacity and consent: ECT requires specific informed consent (or, when capacity is absent, surrogate/court authorization per state law). The American Psychiatric Association's Task Force report on ECT frames consent, indication documentation, and pre-anesthetic evaluation as prerequisites.
• Pre-procedure workup: history and physical with airway assessment, cardiac risk stratification (ACC/AHA perioperative framework for non-cardiac procedures), electrolytes, and imaging only if focal neurologic findings or suspected mass lesion.
• Medication reconciliation: taper or hold benzodiazepines and anticonvulsants (lamotrigine, valproate) — they raise seizure threshold and shorten seizures; lithium is typically held or reduced because of prolonged post-ictal delirium and confusion.

The treatment itself

• Anticholinergic: glycopyrrolate — blunts the initial parasympathetic surge (bradycardia/asystole) and dries secretions.
• Induction agent: ultra-short-acting barbiturate methohexital is the reference agent; etomidate or ketamine are used when seizures are inadequate, as both are less anticonvulsant than propofol.
• Neuromuscular blockade: depolarizing agent succinylcholine prevents tonic-clonic musculoskeletal injury; a blood-pressure cuff isolates one limb so motor seizure duration can be timed.
• Bite block and 100% oxygen with bag-mask ventilation; brief general anesthesia only.
• Electrode placement: right unilateral ultrabrief pulse minimizes cognitive burden; bitemporal is more rapidly effective and is preferred for catatonia, psychotic depression, or urgent suicidality. Stimulus is dosed above the individually titrated seizure threshold.
• Course: typically 2–3 sessions weekly; adequacy is judged by an EEG-confirmed generalized seizure of roughly 25–30 seconds with post-ictal suppression.

Escalation and maintenance

• Inadequate seizure: hyperventilate, increase stimulus intensity, switch anesthetic, or add caffeine/flumazenil augmentation.
• Non-response: convert unilateral to bitemporal placement before abandoning ECT.
• Relapse prevention: continuation/maintenance ECT and/or pharmacotherapy (antidepressant plus lithium) — relapse is high if nothing follows the acute course.
• Alternatives if ECT is refused or unavailable: repetitive TMS, FDA-approved intranasal esketamine (with an oral antidepressant, under REMS), vagus nerve stimulation.

Cognitive (most common, most tested)

• Anterograde amnesia: impaired encoding of new information during the treatment course; hallmark is difficulty recalling conversations or hospital events. Resolves over days to weeks after the course ends.
• Retrograde amnesia: loss of memories from weeks to months before treatment, worst for autobiographical memories; risk is greatest with bitemporal placement and sine-wave (obsolete) stimuli, least with right unilateral ultrabrief pulse. A minority report persistent gaps.
• Post-ictal delirium/emergence agitation: disorientation and combativeness on awakening from confusion of post-ictal state with anesthetic emergence; managed with reorientation, occasionally a short-acting benzodiazepine.

Neurologic emergencies

• Prolonged seizure or status epilepticus (seizure beyond roughly 2–3 minutes): the reason EEG is monitored every session. Emergency — terminate with IV benzodiazepine or additional induction agent.
• Raised intracranial pressure/herniation: the ictal surge in cerebral blood flow and ICP is dangerous in a patient with a space-occupying lesion — the mechanism behind that relative contraindication. Emergency.
• Intracranial hemorrhage from the hypertensive surge in a patient with an unsecured aneurysm or AVM. Emergency.

Cardiovascular (biphasic autonomic response)

• Bradyarrhythmia/asystole: initial parasympathetic (vagal) discharge immediately after stimulus, exaggerated by subconvulsive stimulation or beta blockade. Anticipated with glycopyrrolate; emergency if sustained.
• Tachycardia, hypertension, demand ischemia, arrhythmia, takotsubo cardiomyopathy: the subsequent sympathetic surge; signaled by chest pain, ST changes, or new wall-motion abnormality. Emergency if ischemic.

Anesthetic and mechanical

• Prolonged apnea/paralysis: pseudocholinesterase (butyrylcholinesterase) deficiency prevents succinylcholine hydrolysis — supportive ventilation until it wears off.
• Malignant hyperthermia: succinylcholine trigger; rising end-tidal CO2, masseter rigidity, hyperthermia. Emergency — dantrolene.
• Hyperkalemia with succinylcholine in denervation injury or burns; aspiration from unprotected airway.
• Dental fracture, tongue/lip laceration, jaw pain: direct masseter contraction from stimulus spread, not the seizure — hence the bite block.

• There are no absolute contraindications to ECT: the classic distractor is a stem offering "contraindicated because of pregnancy" or "because of a pacemaker." The highest-risk relative contraindication is a space-occupying lesion with raised intracranial pressure, because the ictal surge in cerebral blood flow can precipitate herniation.
• Pregnancy is an indication, not a barrier: for a severely depressed, actively suicidal, or catatonic pregnant patient, ECT is the answer — no known teratogenicity, with fetal heart-rate monitoring, left uterine displacement, and obstetric availability, consistent with ACOG's framing of untreated severe perinatal depression as itself a major risk.
• Catatonia sequence: lorazepam challenge first, ECT if it fails or if malignant catatonia is present. If a stem gives mutism, waxy flexibility, and negativism, the single best next step is a benzodiazepine trial — not immediate ECT — unless the patient is hyperthermic and autonomically unstable.
• Hold benzodiazepines and anticonvulsants: they raise the seizure threshold and produce inadequate seizures; lithium raises the risk of prolonged post-ictal delirium. This is the most common "why did the seizure fail" stem.
• The autonomic response is biphasic: parasympathetic bradycardia/asystole first (prevented by glycopyrrolate), then a sympathetic hypertensive-tachycardic surge. Asystole immediately after the stimulus is expected physiology, not a device malfunction.
• Succinylcholine associations: prolonged apnea from pseudocholinesterase deficiency, malignant hyperthermia, and hyperkalemia in burns or denervation.
• Memory: anterograde amnesia resolves; retrograde autobiographical amnesia is the deficit that may persist. Right unilateral ultrabrief placement minimizes it; bitemporal works faster but costs more cognition.
• ECT does not cause structural brain injury — hippocampal volume actually increases. Reject any answer choice implying "permanent brain damage."
• Relapse is the rule without follow-through: after remission, continue maintenance ECT and/or pharmacotherapy (antidepressant with lithium).